DPP4 and neurodegenerative disease: Numerous studies have demonstrated that the risk of developing BP is significantly elevated in individuals who have neurodegenerative diseases or use dipeptidyl peptidase-4 inhibitors (gliptins) to treat diabetes (24–27).